

Dong-Hoe Koo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2353225/publications.pdf>

Version: 2024-02-01

60
papers

955
citations

430843

18
h-index

501174

28
g-index

62
all docs

62
docs citations

62
times ranked

1554
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical outcomes and prognostic factors of cone-beam CT-guided radiofrequency ablation for pulmonary metastases in colorectal cancer patients. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2023, 19, .	1.1	1
2	Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients. <i>Cancer</i> , 2022, 128, 995-1003.	4.1	27
3	The first report of K-Umbrella Gastric Cancer Study: An open label, multi-center, randomized, biomarker-integrated trial for second-line treatment of advanced gastric cancer (AGC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 4001-4001.	1.6	5
4	Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study. <i>Cancers</i> , 2021, 13, 331.	3.7	4
5	Clinicopathological characteristics and outcomes of gastrointestinal stromal tumors with high progrenulin expression. <i>PLoS ONE</i> , 2021, 16, e0245153.	2.5	3
6	Value Frameworks: Adaptation of Korean Versions of Value Frameworks for Oncology. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 3139.	2.6	4
7	Trends in Chemotherapy Patterns and Survival of Patients with Advanced Gastric Cancer over a 16-Year Period: Impact of Anti-HER2-Targeted Agent in the Real-World Setting. <i>Cancer Research and Treatment</i> , 2021, 53, 436-444.	3.0	4
8	A multi-institutional phase Ib/II trial of first-line triplet regimen (Pembrolizumab, Trastuzumab,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 467	1.6	31
9	Venous Invasion and Perineural Invasion as Upstaging and Poor Prognostic Factors in NO Gastric Cancers. <i>Anticancer Research</i> , 2021, 41, 5803-5810.	1.1	4
10	New prognostic model for patients with advanced gastric cancer: Fluoropyrimidine/platinum doublet for first-line chemotherapy. <i>World Journal of Gastroenterology</i> , 2021, 27, 8357-8369.	3.3	0
11	Prospective multicentre randomised clinical trial comparing survival rates, quality of life and nutritional status between advanced gastric cancer patients with different follow-up intensities: study protocol for the STOFOLUP trial. <i>BMJ Open</i> , 2021, 11, e056187.	1.9	3
12	Prognostic Value of Progranulin in Patients with Colorectal Cancer Treated with Curative Resection. <i>Pathology and Oncology Research</i> , 2020, 26, 397-404.	1.9	7
13	Middle-aged men with type 2 diabetes as potential candidates for pancreatic cancer screening: a 10-year nationwide population-based cohort study. <i>Acta Diabetologica</i> , 2020, 57, 197-202.	2.5	4
14	Prognostic significance of USP10 and p14ARF expression in patients with colorectal cancer. <i>Pathology Research and Practice</i> , 2020, 216, 152988.	2.3	17
15	Complications after 100 sessions of cone-beam computed tomography-guided lung radiofrequency ablation: a single-center, retrospective experience. <i>International Journal of Hyperthermia</i> , 2020, 37, 763-771.	2.5	5
16	Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 24	1.6	24
17	Oncology, 2020, 38, 3081-3081. Pembrolizumab vs paclitaxel as second-line treatment for Asian patients with PD-L1- positive advanced gastric or gastroesophageal cancer (GC) in the phase III KEYNOTE-063 trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16586-e16586.	1.6	3
18	Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting. <i>Cancer Research and Treatment</i> , 2020, 52, 907-916.	3.0	12

#	ARTICLE	IF	CITATIONS
19	Safety and efficacy of radiofrequency ablation for pulmonary metastases in metastatic colorectal cancer patients: A single center experience.. <i>Journal of Clinical Oncology</i> , 2020, 38, 141-141.	1.6	0
20	Neutrophil-to-lymphocyte ratio and risk of lung cancer mortality in a low-risk population: A cohort study. <i>International Journal of Cancer</i> , 2019, 145, 3267-3275.	5.1	41
21	The Incremental Risk of Pancreatic Cancer According to Fasting Glucose Levels: Nationwide Population-Based Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4594-4599.	3.6	22
22	Risk factors for incident anemia of chronic diseases: A cohort study. <i>PLoS ONE</i> , 2019, 14, e0216062.	2.5	8
23	Efficacy and safety of <i>Viscum album</i> extract (Helixor-M) to treat malignant pleural effusion in patients with lung cancer. <i>Supportive Care in Cancer</i> , 2019, 27, 1945-1949.	2.2	12
24	Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 223-239.	3.0	13
25	Clinicopathological characteristics of patients with gastrointestinal stromal tumor according to progranulin expression.. <i>Journal of Clinical Oncology</i> , 2019, 37, 57-57.	1.6	1
26	Peri-tumor administration of 5-fluorouracil sol-gel using a hollow microneedle for treatment of gastric cancer. <i>Drug Delivery</i> , 2018, 25, 872-879.	5.7	19
27	Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). <i>Gastric Cancer</i> , 2018, 21, 819-830.	5.3	24
28	Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy: Korean Cancer Study Group (KCSG) multicentre prospective study. <i>British Journal of Cancer</i> , 2018, 118, 1169-1175.	6.4	25
29	Prognostic value of progranulin in patients with colorectal cancer underwent curative resection.. <i>Journal of Clinical Oncology</i> , 2018, 36, 696-696.	1.6	0
30	Clinical characteristics and outcomes of metastatic or recurrent gastric cancer with high progranulin expression in patients who had received palliative chemotherapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 83-83.	1.6	0
31	Initial titration with 200 $\frac{1}{4}$ g fentanyl buccal tablets: a retrospective safety analysis in Korean cancer patients. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 577-584.	1.7	2
32	The significance of the trial outcome was associated with publication rate and time to publication. <i>Journal of Clinical Epidemiology</i> , 2017, 84, 78-84.	5.0	27
33	Antiemetic Corticosteroid Rotation from Dexamethasone to Methylprednisolone to Prevent Dexamethasone-Induced Hiccup in Cancer Patients Treated with Chemotherapy: A Randomized, Single-Blind, Crossover Phase III Trial. <i>Oncologist</i> , 2017, 22, 1354-1361.	3.7	24
34	Practice Patterns Regarding Multidisciplinary Cancer Management and Suggestions for Further Refinement: Results from a National Survey in Korea. <i>Cancer Research and Treatment</i> , 2017, 49, 1164-1169.	3.0	8
35	Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor. <i>Cancer Research and Treatment</i> , 2016, 48, 1155-1166.	3.0	142
36	Progranulin as a predictive factor of response to chemotherapy in advanced biliary tract carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 1085-1092.	2.3	12

#	ARTICLE	IF	CITATIONS
37	Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 339-347.	2.3	4
38	Field Cancerization in Sporadic Colon Cancer. <i>Gut and Liver</i> , 2016, 10, 773-780.	2.9	30
39	Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 173-182.	2.3	37
40	Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer. <i>Tumor Biology</i> , 2015, 36, 5865-5871.	1.8	17
41	EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 197-206.	2.3	26
42	Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 933-937.	2.3	3
43	Ethical Attitudes according to Education and Clinical Experience of Do-Not-Resuscitate (DNR). <i>The Korean Journal of Hospice and Palliative Care</i> , 2015, 18, 208-218.	0.7	1
44	A Rare Case of Acute Leukemic Presentation of Blastic Plasmacytoid Dendritic Cell Neoplasm without Cutaneous Lesions. <i>Annals of Laboratory Medicine</i> , 2014, 34, 148-151.	2.5	4
45	Serum CA19-9 as a prognostic factor in patients with metastatic gastric cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013, 9, 324-330.	1.1	28
46	Diagnosis and Treatment of Gastrointestinal Stromal Tumor. <i>Korean Journal of Medicine</i> , 2013, 85, 341.	0.3	4
47	Burnt-out Metastatic Prostate Cancer. <i>Yeungnam University Journal of Medicine</i> , 2013, 30, 116.	0.1	0
48	Venous thromboembolism (VTE) in patients with advanced gastric cancer: An Asian experience. <i>European Journal of Cancer</i> , 2012, 48, 492-500.	2.8	38
49	Aggressive Classical Kaposi's Sarcoma Mimicking Malignant Lymphoma. <i>Pathology and Oncology Research</i> , 2012, 18, 1067-1069.	1.9	1
50	Progranulin as a Prognostic Biomarker for Breast Cancer Recurrence in Patients Who Had Hormone Receptor-Positive Tumors: A Cohort Study. <i>PLoS ONE</i> , 2012, 7, e39880.	2.5	44
51	Three-week combination chemotherapy with S-1 and cisplatin as first-line treatment in patients with advanced gastric cancer: a retrospective study with 159 patients. <i>Gastric Cancer</i> , 2012, 15, 305-312.	5.3	9
52	Prognostic Value of Immunohistochemical Biomarkers at Different Cut-off Values in Patients with Diffuse Large B-cell Lymphoma Treated with CHOP Chemotherapy. <i>Journal of Korean Medical Science</i> , 2011, 26, 1556.	2.5	8
53	A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 913-921.	2.3	69
54	Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study. <i>BMC Cancer</i> , 2011, 11, 205.	2.6	46

#	ARTICLE	IF	CITATIONS
55	Adjuvant Chemotherapy for Small Bowel Adenocarcinoma after Curative Surgery. <i>Oncology</i> , 2011, 80, 208-213.	1.9	21
56	Abstract 2238: Clinical characteristics and outcome of patients with Rituximab-CHOP resistant/refractory DLBCL: Presence of B symptom and high LDH at diagnosis predict survival. , 2011, , .		0
57	<i>Pneumocystis jiroveci</i> Pneumonia Mimicking Miliary Tuberculosis in a Kidney Transplanted Patient. <i>Tuberculosis and Respiratory Diseases</i> , 2009, 67, 127.	1.8	1
58	A Phase II Study of Cetuximab (Erbix [®]) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer. <i>Journal of Korean Medical Science</i> , 2007, 22, S98.	2.5	12
59	Monoclonal Proteinuria as a Prognostic Factor for Multiple Myeloma Patients with Intact Immunoglobulin Type. <i>The Korean Journal of Hematology</i> , 2007, 42, 276.	0.7	0
60	Skin Necrosis after a Low-Dose Vasopressin Infusion through a Central Venous Catheter for Treating Septic Shock. <i>Korean Journal of Internal Medicine</i> , 2006, 21, 287.	1.7	14